37
Total investments
25
Early stage
9
Mid stage
0
Late stage
15y
Years active
Portfolio
37 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor, Board Member
Dec 2025
ElectronX (EXI), the first U.S.-regulated, direct-access power derivatives market, is the energy exchange created to address volatile short-term price exposure to electricity. With locations in Chicago and New York City, ElectronX is helping to expand the nations power grid by building the financial infrastructure and risk management tools necessary to support increased investment in energy generation, renewable resources, and battery storage technology.
ElectronX is proud to be supported by premier venture capital, quantitative trading, and global energy firms including Innovation Endeavors, DCVC, Systemiq Capital, Equinor Ventures, Shell Ventures, XTX Markets, Five Rings, NGP, GTS, Amplo, BoxGroup, JACS Capital, and Lightning Capital.
For more information, please visit electronx.com.
Investor, Board Member
Oct 2025
At Weave Bio, we’re building the backbone for modern drug development. Drug development teams deserve tools that match the pace and complexity of their science. Our AI-native platform supports biotech and pharma organizations at every step, with a focus on regulatory workflows that bring clarity, connection, and efficiency to documentation so therapies can move forward without unnecessary delays.
We partner with scientists, clinicians, and regulatory professionals who are advancing the next generation of medicines. By improving the processes behind regulatory documentation, Weave helps reduce bottlenecks and frees teams to focus on what matters most — discovery, innovation, and patient impact.
Our approach is human-driven and technology-powered. We believe that combining scientific expertise with AI innovation can transform how life sciences organizations operate, making the development of therapies more efficient, compliant, and collaborative.
Weave is a small but mighty team of scientists, engineers, and industry experts united by a shared mission: helping life-changing medicines reach patients faster. Our collective experience across biotechnology, software, and regulation gives us deep insight into the challenges of drug development — and the passion to build solutions that make a lasting impact.
We’re proud to work side by side with our partners to move science forward and build the foundation that drug development teams need today and tomorrow.
Investor
Apr 2024
Augment is the AI coding platform built for enterprises - powered by a highly secure, production-grade Context Engine developed over 2.5 years in stealth until our public launch in November 2024.
Augment semantically indexes your entire codebase, documentation, dependencies, and internal knowledge in real time to enable devs to ship code faster, onboard in days instead of months, and modernize legacy systems with confidence.
We are alumni of global-leading AI and cloud companies including Google, Meta, NVIDIA, Snowflake, and Databricks - all on a mission to provide enterprises with context that actually understands your codebase.
If, like us, you believe in augmenting and not replacing software developers, join us on our mission to improve software development at scale using AI.
Board Member
2019
We build scalable quantum computers with atomic arrays that empower our customers to achieve computational breakthroughs.
Board Member
2019
Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells.
By directly measuring the effects of chemical compounds on the behavior of protein molecules in a live cellular environment, Eikon’s landmark assays facilitate the highly sensitive identification of compound-protein interactions that could not be identified through traditional assays, thereby unlocking otherwise intractable classes of proteins as drug targets. Furthermore, the ability to directly visualize protein mechanisms in disease coupled with the extraordinarily high-powered high-content data sets generated by Eikon’s drug-screening technology enable an unprecedented opportunity to quantitatively explore novel biology in the living cell. These insights facilitate creation and application of data-driven hypotheses to the discovery of life-saving therapies.
Eikon is seeking adventurous, passionate and creative team members eager to apply their talents to empower interdisciplinary scientific exploration, inaugurate a radical drug-discovery paradigm, and ultimately create novel medicines. To learn more about open positions, please visit: https://www.eikontx.com/join-us/#open-positions
Board Member and Investor
2018
Hi, we’re Farmer’s Fridge. We make it simple for everyone to eat fresh, healthy meals, whether you’re on the go or at home.
We started with a network of smart Fridges, designed to make finding fresh & healthy meals as simple as vending a candy bar. Today, we have more than 1000 Fridges all over the country in airports, hospitals, office buildings, universities and more.
However you found us, we’re glad you’re here, and we’re excited to feed you!
Board Member
2018
Hi, we’re Farmer’s Fridge. We make it simple for everyone to eat fresh, healthy meals, whether you’re on the go or at home.
We started with a network of smart Fridges, designed to make finding fresh & healthy meals as simple as vending a candy bar. Today, we have more than 1000 Fridges all over the country in airports, hospitals, office buildings, universities and more.
However you found us, we’re glad you’re here, and we’re excited to feed you!
Board Member
2018
At Vicarious Surgical we are revolutionizing the field of surgical robotics. We seek to improve the lives of patients, enhance the ability of surgeons, and expand worldwide access to high-quality care through the use of surgical robotics. We have reimagined what is possible by building a human-like surgical robot and combining it with the world’s first virtual-reality surgical camera to allow surgeons to perform minimally-invasive surgery with the ease of an open procedure.
Board Member
2018
Gatik is in the business of autonomous freight.
We run driverless delivery networks across North America for some of the world’s largest retailers and consumer brands.
Board Member and Investor
2018
At Vicarious Surgical we are revolutionizing the field of surgical robotics. We seek to improve the lives of patients, enhance the ability of surgeons, and expand worldwide access to high-quality care through the use of surgical robotics. We have reimagined what is possible by building a human-like surgical robot and combining it with the world’s first virtual-reality surgical camera to allow surgeons to perform minimally-invasive surgery with the ease of an open procedure.
Investor, Board Member
May 2017
GRO Biosciences transforms protein therapeutics with new amino acid building blocks to treat incurable diseases.
Show all 37 investments ↓
Experience · 39 entries
All (39)
Investments (37)
Founder (1)
Board (20)
2026
2025
Investor, Board Member
Dec 2025
ElectronX (EXI), the first U.S.-regulated, direct-access power derivatives market, is the energy exchange created to address volatile short-term price exposure to electricity. With locations in Chicago and New York City, ElectronX is helping to expand the nations power grid by building the financial infrastructure and risk management tools necessary to support increased investment in energy generation, renewable resources, and battery storage technology.
ElectronX is proud to be supported by premier venture capital, quantitative trading, and global energy firms including Innovation Endeavors, DCVC, Systemiq Capital, Equinor Ventures, Shell Ventures, XTX Markets, Five Rings, NGP, GTS, Amplo, BoxGroup, JACS Capital, and Lightning Capital.
For more information, please visit electronx.com.
Investor, Board Member
Oct 2025
At Weave Bio, we’re building the backbone for modern drug development. Drug development teams deserve tools that match the pace and complexity of their science. Our AI-native platform supports biotech and pharma organizations at every step, with a focus on regulatory workflows that bring clarity, connection, and efficiency to documentation so therapies can move forward without unnecessary delays.
We partner with scientists, clinicians, and regulatory professionals who are advancing the next generation of medicines. By improving the processes behind regulatory documentation, Weave helps reduce bottlenecks and frees teams to focus on what matters most — discovery, innovation, and patient impact.
Our approach is human-driven and technology-powered. We believe that combining scientific expertise with AI innovation can transform how life sciences organizations operate, making the development of therapies more efficient, compliant, and collaborative.
Weave is a small but mighty team of scientists, engineers, and industry experts united by a shared mission: helping life-changing medicines reach patients faster. Our collective experience across biotechnology, software, and regulation gives us deep insight into the challenges of drug development — and the passion to build solutions that make a lasting impact.
We’re proud to work side by side with our partners to move science forward and build the foundation that drug development teams need today and tomorrow.
Show all 39 entries ↓
Investment activity
2011–2026 · 37 investments
Recent (last 2 years)Earlier
